GERD (acid reflux) Board decisions

The Board denied an initial rating in excess of 10 percent for GERD and remanded the claims for service connection for chronic fatigue syndrome, a back disability, and sinusitis.

The Board granted a 10 percent evaluation for the Veteran's GERD, finding that his condition is productive of daily medications to control dysphagia and is otherwise asymptomatic.

The Board denied the claims for an initial compensable rating for left ear sensorineural hearing loss, service connection for a right ear hearing loss disability, and a left eye disorder. However, it granted service connection for a back disability and radiculopathy of both lower extremities as secondary to the back disability.

The Board remands the claims for service connection for maxillary and ethmoid sinusitis, headaches, and an initial rating in excess of 10 percent for GERD due to insufficient medical evidence.

The Board granted service connection for erectile dysfunction and denied service connection for left foot tendonitis. The Veteran's gastroesophageal reflux disease and bilateral pes planus with plantar fasciitis were rated in excess of 10 percent and 50 percent, respectively.

The Board granted the restoration of a 30 percent evaluation for dermatophytosis, onychomycosis, and calluses of the feet due to an improper reduction. The claim for service connection for GERD was remanded for further development.

The Veteran was awarded service connection for allergic rhinitis based on the PACT Act, but an earlier effective date prior to August 10, 2022, is not warranted.

The Board denied the veteran's claims for increased ratings for PTSD and bilateral hearing loss, as well as service connection for kidney disease, GERD, bilateral knee condition, and bilateral arm condition. The TDIU claim was remanded.

The Board remands the claims for service connection for squamous cell carcinoma, actinic keratosis, GERD, and Barrett's esophagus due to insufficient evidence regarding their relationship to in-service sun exposure or service-connected hypertension.

The Board remands the issue of service connection for GERD due to an inadequate VA opinion.

The Board granted a rating of 60 percent from January 27, 2016 to July 7, 2022 for the Veteran's duodenal ulcer, duodenitis, gastritis, and gastroesophageal reflux disease (GERD).

The Board granted a 30 percent disability rating for GERD and hiatal hernia, effective March 31, 2020, but denied an earlier effective date and a higher initial rating.

The appeal for service connection for gastroesophageal reflux disease and a right knee condition was withdrawn by the Veteran during a Board hearing.

The Board granted service connection for gastrointestinal reflux disease (GERD) on a direct basis, resolving reasonable doubt in the Veteran's favor.

The Board denied service connection for vertigo, incontinence, and GERD due to the lack of evidence supporting current diagnoses. The claims for hematuria and hemorrhoids were remanded for further development.

The Board denied service connection for gastroesophageal reflux disease (GERD) and obstructive sleep apnea (OSA), finding no evidence of a relationship to the Veteran's active duty, including exposure to burn pits.

The Board remands the claims for service connection for GERD and right side umbilical hernia to obtain additional medical opinions.

The Veteran's service-connected hypertension is granted a 10 percent disability rating, and service connection for gastroesophageal reflux disease (GERD) is granted due to exposure to environmental toxins while serving in Southwest Asia.

The veteran's claims for service connection for various conditions were denied, except for tinnitus and bilateral hearing loss disability which were granted. The veteran was also granted service connection for hypertension.

The Board granted service connection for bilateral hearing loss, arthritis of the cervical spine, cervical radiculopathy of the left arm, back disability, left elbow condition, left shoulder condition, left wrist condition, left hand condition, hypertension, and an initial rating of 10 percent for coronary arteriosclerosis prior to September 24, 2024.